Stay updated on Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.7%
    Check dated 2025-06-20T13:11:48.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.3.
    Difference
    0.1%
    Check dated 2025-06-13T10:11:16.000Z thumbnail image
  4. Check
    32 days ago
    Change Detected
    Summary
    The web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.
    Difference
    1%
    Check dated 2025-05-29T23:15:20.000Z thumbnail image
  5. Check
    40 days ago
    Change Detected
    Summary
    The web page has been updated to version 2.16.0, replacing the previous version 2.15.2.
    Difference
    0.2%
    Check dated 2025-05-22T21:15:02.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-05-01T04:54:43.000Z thumbnail image
  7. Check
    76 days ago
    Change Detected
    Summary
    The webpage has undergone significant changes, including the removal of detailed information about a phase II trial studying nivolumab and ipilimumab for treating renal medullary carcinoma, while adding new identifiers and collaborators related to the study.
    Difference
    58%
    Check dated 2025-04-16T14:36:25.000Z thumbnail image

Stay in the know with updates to Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial page.